Mounjaro and tirzepatide: what's the relationship between them?

Step 1: understanding what you're actually injecting

When a prescriber writes a prescription for Mounjaro, they are prescribing tirzepatide, these are not two options or two products. Tirzepatide is the international non-proprietary name (the scientific name recognised by regulators worldwide), and Mounjaro is the trade name Eli Lilly chose for the UK and other markets. The pen you inject, the molecule doing the work, and the clinical trial evidence behind it all belong to tirzepatide, a medicine worth understanding in its own right before you begin. If you've seen both names on a forum or a news article and wondered whether they describe different things, they don't.

The NHS medicines information page for tirzepatide covers both names clearly and is a useful starting point if you want the patient-level detail from a regulated UK source.

One practical note: because Mounjaro is the licensed brand in the UK, that's the name you'll see on a UK prescription and on the packaging your pharmacy dispenses. If you're still working out whether to think of this medicine as Mounjaro or tirzepatide, it's a common question and the short answer is that they're the same thing, with Mounjaro being the only form in which you can obtain it here through legitimate channels.

Step 2: what makes tirzepatide's mechanism different from other injections

Most weight-loss injections on the UK market target a single gut hormone receptor, the GLP-1 receptor, which helps regulate appetite and slows gastric emptying. Tirzepatide does that too, but it also activates the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is a separate gut hormone involved in energy storage and appetite signalling. Activating both pathways together appears to produce a more substantial reduction in appetite and caloric intake than targeting GLP-1 alone, which is reflected in the trial data.

In the SURMOUNT-1 trial (a large phase 3 study involving 2,539 adults with obesity and no type 2 diabetes) participants on the highest tirzepatide dose saw an average body-weight reduction of around 20 to 21 percent over 72 weeks, compared with around 3 percent in the placebo group. Those figures come from the published paper in the New England Journal of Medicine. If you want to understand the detail of the mechanism itself, the full explanation of how tirzepatide works covers the dual-receptor pathway in plain terms.

The dual-agonist design is also why tirzepatide is sometimes discussed alongside semaglutide (Wegovy) as a comparison rather than as an equivalent. They share a class but not a mechanism, and the available head-to-head evidence suggests the distinction matters for weight outcomes.

Step 3: the licensed use in the UK and who it's for

In the UK, Mounjaro (tirzepatide) is licensed for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above if at least one weight-related condition is present, things like high blood pressure, high cholesterol, prediabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK guidance; a prescriber will go through this with you properly. The medicine is used alongside a reduced-calorie diet and increased physical activity, it is not a standalone fix.

It is also licensed for type 2 diabetes management, so you may occasionally see it discussed in a diabetes context. The licence covers both, but if you're approaching it from a weight-management angle, the eligibility questions your prescriber works through are centred on your BMI and any relevant health conditions. NICE's appraisal of tirzepatide (TA1026) gives the formal recommendations for NHS use, which carry stricter criteria than the private licensed eligibility, you can read the detail at NICE TA1026.

For a fuller picture of everything the licence covers, the Mounjaro overview page brings together eligibility, the treatment schedule, and what private access involves. And if you're trying to work out whether you'd be a suitable candidate, the eligibility guide walks through the prescriber's assessment criteria in plain terms. Cost is a reasonable question at this stage too, the background on Eli Lilly's 2025 UK price change gives useful context on why private prices vary between providers.

Step 4: what this means if you're considering starting treatment

Because Mounjaro is a Prescription-Only Medicine, the route to it is the same regardless of where you read about tirzepatide first: a clinical assessment by a qualified prescriber who can confirm it's suitable for you specifically. No pharmacy can dispense it and no platform can approve it without that step.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, the same day you submit. There's no algorithm making the call. People sometimes ask whether timing matters for getting started (Monday mornings, payday, the week before a holiday) and honestly, the process is the same whenever you submit; orders received by 12pm on a working day are dispatched that afternoon once clinically approved, with free next-working-day tracked delivery by DPD.

If you have broader questions about the range of options available, the treatment overview sets out what's licensed in the UK and how the different medicines compare. Our FAQs cover the questions that come up most often before a first consultation. When you're ready, you can begin the process through the free consultation, there's no obligation to proceed, and no charge for the clinical review itself.